<DOC>
	<DOCNO>NCT00477386</DOCNO>
	<brief_summary>Based pre-clinical data , generate group , investigator propose test phase I/II clinical trial follow hypothesis : demethylation induce decitabine result re-sensitization platinum recurrent ovarian cancer . To test hypothesis , investigator treat patient recurrent ovarian cancer platinum resistant ( recurrence within 6 month platinum therapy ) platinum-refractory ( response platinum ) combination consist decitabine carboplatin . This institutional open label phase I/II trial determine safety biologic activity Decitabine/Carboplatin combination . The investigator determine whether Carboplatin safely combine Decitabine , optimal dose schedule investigator define whether dosage , regimen biologically active ( i.e . induces demethylation target gene ) . In second part trial , investigator determine clinical activity combination population patient platinum-resistant ovarian cancer .</brief_summary>
	<brief_title>Trial Decitabine Sensitizer Carboplatin Platinum Resistant Recurrent Ovarian Cancer</brief_title>
	<detailed_description>Decitabine escalate dose level give IV X 5 day follow Carboplatin give IV Day 8 dose correspond area curve ( AUC ) 5 . The maximum dose Decitabine ( 20 mg/m2 ) base result myelodysplastic syndrome ( MDS ) clinical trial demonstrate biological clinical efficacy dose ( 15-17 ) . It recognize high dos decitabine administer , myelotoxicity significant adverse event . This protocol assess low less toxic biologically active dose . Decitabine dose escalate follow . Dose level -1 : 5 mg/m2 IV per day ( QD ) X 5 day Dose level 1 : 10mg/m2 IV QD X 5 day Dose level 2 : 20mg/m2 IV QD X 5 day Each cycle consist 28 day , delay allow blood count recovery . Correlative blood draw occur Day1 ( baseline ) Day 8 Carboplatin cycle 1 2 . The escalation phase follow standard 3+3 design . That , patient accrue dose level cohort 3-6 patient . Escalation continue DLT observe , high dose-level reach , medical judgment indicate . The goal phase I cohort ensure safety tolerability combination , define maximum tolerate dose . An initial 3 patient enrol dose level 1 . If 3 patient dose level 1 complete 4 week therapy without dose limit toxicity ( DLT ) , study proceed enroll 3 patient dose level 2 . If 3 patient dose level 2 complete 4 week therapy without DLT , accrue 3 ensure 0 1 6 DLT proceed phase II cohort . As dose level 2 represent full dos agent , dose escalation beyond dose level 2 .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Have recurrent epithelial ovarian cancer , primary peritoneal carcinomatosis fallopian tube cancer . Have platinumresistant ( recurrence within 6 month platinumcontaining regimen ) platinum refractory ( progression platinum ) disease Have measurable disease accord RECIST detectable disease . Measurable disease define presence least one unidimensionally measurable lesion great equal 20 mm conventional technique , include palpation , plain xray , CT scan MRI , great equal 10 mm spiral CT scan . Detectable disease define patient one measurable disease least one follow condition : 1 ) Baseline value cancer antigen 125 ( CA125 ) least twice upper limit normal ; 2 ) Ascites and/or pleural effusion attribute tumor ; 3 ) solid and/or cystic abnormality radiographic image meet RECIST definition target lesion . &gt; /= 18 year age . Give write , informed consent participation protocol . Be least 4 week last treatment allow recovery prior toxicity ( exception hormonal therapy , 1week washout period radiation therapy 3week washout period sufficient ) . Patients come experimental therapy biological agent expect cause myelotoxicity treatment least 3 week washout period . Have disease progress within 6 month platinumbased chemotherapeutic regimen . Have history platinum allergy . Have negative serum pregnancy test prior study entry practice effective form contraception hysterectomy and/or oophorectomy part prior treatment . It expect overwhelming majority ovarian cancer patient would hysterectomy oophorectomy part original surgery . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Have acceptable organ function , evidence laboratory data : Aspartate aminotransferase alanine aminotransferase less 2.5 time upper limit normal ( ULN ) Direct bilirubin le 1.5 time ULN Alkaline phosphatase less 2.5 time ULN Absolute neutrophil count great equal 1500 cells/mm3 White cell blood count great 3000cells/mm3 Hemoglobin great equal 9.0 g/dL ( posttransfusion ) Platelets great 100,000/mm3 ( posttransfusion ) Creatinine level less 1.5 time ULN Not participate clinical trial involve conventional investigational drug device within previous 3 week . Not grade 2 great neuropathy . Have additional active cancer addition epithelial ovarian cancer within last 5 year , exception superficial skin cancer ( basal cell squamous cell skin carcinoma ) , carcinoma situ cervix , Stage I endometrial cancer le 50 % invasion myometrium , adequately treated Stage I II cancer complete remission . Be free active infection require antibiotic treatment . Not additional uncontrolled serious medical condition psychiatric illness . Not immune deficiency receive combination antiretroviral therapy Not know brain metastasis , progressive neurologic dysfunction may develop , would confound evaluation neurologic adverse event . Absence uncontrolled hypertension , arrhythmia , congestive heart failure angina . Patients myocardial infarction cardiac surgery lease 6 month event free active symptom .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>recurrent ovarian cancer</keyword>
	<keyword>platinum resistant</keyword>
	<keyword>decitabine</keyword>
</DOC>